Catalent Announces New Organization To Speed New Products To Market

Somerset, N.J.  — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has today announced that Sharon Johnson, Senior Vice President, Global Quality & Regulatory Affairs, is to head up Catalent's newly formed Quality, Product Development & Regulatory Affairs organization, established to further build upon Catalent's leadership in new product development, regulatory excellence, reliable supply and quality.

One of the key functions of the new organization will be to focus further on partnering with customers as part of Catalent's New Product Introduction Excellence program. An important factor in Catalent's revenue and growth strategy, the program has expanded at a rate of over 70% over the past three years, from 59 new product launches globally in 2012, to 97 in 2013, and 175 in 2014. 

"The overall goal of the Quality, Product Development & Regulatory Affairs organization will be to drive excellence and reliability across all of the products that we make and deliver," explained Johnson. "Our customer promise is not only to provide a reliable supply of their current, ongoing products, but to deliver new products with the same rigorous commitment to excellence. Bringing together these two functions into one team will tighten collaboration and the partnerships across the organization which are needed to bring more new, innovative and life-saving products to market quicker."

Ms. Johnson will oversee a global function that includes more than 1,500 scientists, quality professionals and regulatory affairs experts. Catalent's 300 R&D scientists work across 20 global development teams to develop up to 500 new products at any one time. Catalent's Quality and Regulatory Affairs teams have helped the company gain accreditation by over 30 global agencies, to supply more than 7,000 products to over 1,000 customers. These products are delivered to over 80 countries, with Catalent maintaining a 100% success rate on new Pre-Approval Inspections (PAIs), and a regulatory inspections outcome rate that is two times better than the industry average.

Prior to assuming her new responsibilities, Ms. Johnson had served as Catalent's Senior Vice President, Global Quality & Regulatory Affairs since 2009, having overseen the roll-out of Catalent's Global Quality Management system to over 20 global sites. Ms. Johnson has thirty-plus years of experience in the pharmaceutical industry, including API and multiple dosages forms, from discovery and launch of NCEs and life cycle management. Prior to joining Catalent, Ms. Johnson served as Vice President of Quality for GE Healthcare's Medical Diagnostic Division, having previously worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.

Ms. Johnson holds a postgraduate Diploma in Industrial Pharmaceutical Studies with Distinction from Brighton University and a BS Honours degree in Biological Sciences/Microbiology from North East Surrey College of Technology.

Media Contacts: 
Chris Halling
+44 (0)7580 041073
[email protected]

Richard Kerns
+44 (0) 161 728 5880
[email protected] 


Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

This press release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as "believe," "expect," "anticipate", "intend", "estimate", "plan", "project", "foresee", "likely", "may", "will", "would" or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent, Inc.'s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption "Risk Factors" in its Annual Report on Form 10-K for the fiscal year ended June 30, 2014 filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent, Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.